← Back to Search

E-Cigarette Variations for Youth Vaping Behavior

N/A
Recruiting
Led By Theodore L Wagener, PhD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
21-25 years old
Willing to complete five, 6 hour lab visits
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 35 minutes
Awards & highlights

Study Summary

This trial looks at how nicotine form, concentration, and flavor affects youth vaping behavior and health.

Who is the study for?
This trial is for young adults aged 21-25 who exclusively use e-cigarettes daily for the last 3 months. Participants must abstain from all tobacco and nicotine for 12 hours before lab sessions, commit to five lab visits, and not be pregnant or breastfeeding. Those with unstable psychiatric conditions, recent heart issues, frequent marijuana use, other tobacco product use, or lung diseases like asthma are excluded.Check my eligibility
What is being tested?
The study investigates how different forms of nicotine in e-cigarettes (varying in concentration and flavor) affect vaping habits and health outcomes in youth. It involves multiple lab sessions where participants' responses to these variations are observed.See study design
What are the potential side effects?
While specific side effects aren't listed here, potential risks may include throat irritation, coughing, dry mouth or throat; increased heart rate or blood pressure; headaches; dizziness; nausea; changes in taste perception.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 21 and 25 years old.
Select...
I am willing to attend five 6-hour lab visits.
Select...
I have been exclusively using e-cigarettes daily for the last 3 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0, 5, 10, 35 min.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0, 5, 10, 35 min. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Airway Inflammation (NIOX VERO)
Average Puff duration
Average Puff volume
+3 more
Secondary outcome measures
Drug Effects/Liking Questionnaire
E-cigarette Purchase Task
Sensory E-Cigarette Expectancies Scale (SEES)
+5 more

Trial Design

8Treatment groups
Experimental Treatment
Group I: Low concentration nicotine salt (1%), Tobacco flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group II: Low concentration nicotine salt (1%), Menthol flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group III: Low concentration free-base nicotine (1%), Tobacco flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group IV: Low concentration free-base nicotine (1%), Menthol flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group V: High concentration nicotine salt (5%), Tobacco flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group VI: High concentration nicotine salt (5%), Menthol flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group VII: High concentration free-base nicotine (5%), Tobacco flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group VIII: High concentration free-base nicotine (5%), Menthol flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
320 Previous Clinical Trials
290,141 Total Patients Enrolled
Theodore L Wagener, PhDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
4 Previous Clinical Trials
2,002 Total Patients Enrolled
Marielle Brinkman, BSPrincipal InvestigatorOhio State University

Media Library

ECIG lab session 2 Clinical Trial Eligibility Overview. Trial Name: NCT05458895 — N/A
E-Cigarette Use Research Study Groups: Low concentration nicotine salt (1%), Menthol flavor, Low concentration nicotine salt (1%), Tobacco flavor, Low concentration free-base nicotine (1%), Menthol flavor, High concentration free-base nicotine (5%), Tobacco flavor, High concentration free-base nicotine (5%), Menthol flavor, High concentration nicotine salt (5%), Menthol flavor, Low concentration free-base nicotine (1%), Tobacco flavor, High concentration nicotine salt (5%), Tobacco flavor
E-Cigarette Use Clinical Trial 2023: ECIG lab session 2 Highlights & Side Effects. Trial Name: NCT05458895 — N/A
ECIG lab session 2 2023 Treatment Timeline for Medical Study. Trial Name: NCT05458895 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are we hoping to discover or achieve with this clinical trial?

"The main goal of this trial, which will be evaluated over the course of 35 minutes, is to assess lung function. Additionally, the study will also collect data on Tiffany-Drobes Questionnaire of Smoking Urges: Brief Form (E-cig craving/suppression of craving and withdraw), E-cigarette Purchase Task (Behavioral economic demand), and Timeline Followback (TLFB) (Background measures)."

Answered by AI

Are people still being accepted to participate in this experiment?

"This medical study, which was first posted on December 2nd 2021, is actively recruiting patients according to clinicaltrials.gov."

Answered by AI

Can this research be conducted on elderly individuals?

"The age range for participants in this trial is 21-25 years old."

Answered by AI

Can I sign up for this experiment?

"We are looking for 75 e-cigarette users, aged 21-25, who fit the following profile: Current exclusive e-cigarette user (>= 1 vaping bout per day) for at least the past 3 months (confirmed in lab by salivary cotinine), 21-25 years old, Willing to abstain from all tobacco and nicotine for at least 12 hours prior to lab sessions, Willing to complete five, 6 hour lab visits, Able to read and speak English, Willing to provide informed consent."

Answered by AI
~23 spots leftby Mar 2025